{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:36:39Z","timestamp":1787506599465,"version":"build-2736575974"},"reference-count":182,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2021,11,2]]},"DOI":"10.1080\/13543776.2021.1940138","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T11:02:11Z","timestamp":1623754931000},"page":"1009-1043","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["Recent updates on Wnt signaling modulators: a patent review (2014-2020)"],"prefix":"10.1080","volume":"31","author":[{"given":"Vishalgiri G.","family":"Goswami","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-425X","authenticated-orcid":false,"given":"Bhumika D.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(82)90409-3"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/307131a0"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/0012-1606(76)90108-1"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/287795a0"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.14.1.59"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90633-A"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7290260"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.24.3286"},{"key":"cit0009","doi-asserted-by":"crossref","unstructured":"Pfister AS, K\u00fchl M. Of Wnts and ribosomes. Progress in molecular biology and translational science. Vol. 153. Elsevier; 2018. p. 131\u2013155.","DOI":"10.1016\/bs.pmbts.2017.11.006"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1242\/dev.01117"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.4161\/org.4.2.5851"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1186\/jbiol22"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8080073"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.3390\/genes9020101"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80324-4"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-101"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.697615"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.20195"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/S1534-5807(03)00266-1"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3470"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2871"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmr079"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080826"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60802-3"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2017.08.015"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.486"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/359235a0"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5307.1787"},{"issue":"1","key":"cit0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6169-0","volume":"20","author":"Arnold A","year":"2020","journal-title":"BMC Cancer"},{"issue":"14","key":"cit0030","first-page":"3346","volume":"59","author":"Mirabelli-Primdahl L","year":"1999","journal-title":"Cancer Res"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036565"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23350"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00227"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701509104"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109083"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R400019200"},{"key":"cit0037","first-page":"2014:318714","author":"Caliceti C","year":"2014","journal-title":"Biomed Res Int"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000445"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.189761"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1242\/dev.018853"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2099"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0075-9"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015040449"},{"key":"cit0044","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhou CJ, Liu Y. Wnt signaling in kidney development and disease. Progress in molecular biology and translational science. Vol. 153. Elsevier; 2018. p. 181\u2013207.","DOI":"10.1016\/bs.pmbts.2017.11.019"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201608-586AW"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414275200"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507609102"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.fcl.2005.01.013"},{"key":"cit0049","unstructured":"A study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses of SM04755 following topical administration to healthy subjects, Clinicaltrial.gov. [cited 2020 Dec 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03229291"},{"key":"cit0050","author":"Deshmukh V","year":"2020","journal-title":"J Orthop Res"},{"key":"cit0051","unstructured":"Extension study evaluating the safety and efficacy of a second year of use of lorecivivint in subjects with osteoarthritis of the knee clinical trials.gov. [cited 2020 Dec 3]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04520607"},{"key":"cit0052","unstructured":"[cited 2020 Dec 3]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800040429"},{"key":"cit0053","unstructured":"A study evaluating the efficacy and safety of SM04554 topical solution in male subjects with androgenetic alopecia. clinicaltrials.gov. [cited 2020 Dec 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03742518"},{"key":"cit0054","unstructured":"A study of LGK974 in patients with malignancies dependent on Wnt ligands Clinicaltrials.gov. [cited 2020 Dec 5]. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01351103?term=LGK-974&draw=2&rank=1"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v11.i7.398"},{"key":"cit0056","unstructured":"Study of WNT974 in combination with LGX818 and cetuximab in patients with BRAF-mutant metastatic colorectal Cancer (mCRC) and Wnt pathway mutations. Clinicaltrials.gov. [cited 2020 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02278133?term=LGK-974&draw=2&rank=3"},{"key":"cit0057","unstructured":"Study to evaluate the safety and tolerability of RXC004 in advanced malignancies. Clinicaltrials.gov. [cited 2020 Dec 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03447470?term=RXC-004&draw=2&rank=1"},{"key":"cit0058","unstructured":"A study to evaluate the safety and tolerability of ETC-1922159 in advanced solid tumours. Clinicaltrials.gov. [cited 2020 Dec 10]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02521844?term=ETC-159&draw=2&rank=1"},{"key":"cit0059","unstructured":"Phase 1 dose escalation study of CGX1321 in subjects with advanced gastrointestinal tumors. Clinicaltrials.gov. [cited 2020 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03507998?term=CGX-1321&draw=2&rank=1"},{"key":"cit0060","unstructured":"Safety and efficacy study of PRI-724 in subjects with advanced myeloid malignancies. Clinicaltrials.gov. [cited 2020 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01606579?term=PRI-724&draw=2&rank=6"},{"key":"cit0061","unstructured":"Safety and efficacy study of PRI-724 plus gemcitabine in subjects with advanced or metastatic pancreatic adenocarcinoma. Clinicaltrials.gov. [cited 2021 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764477?term=PRI-724&draw=2&rank=2"},{"key":"cit0062","unstructured":"Phase I, open-label, non-randomized study to evaluate safety of BC2059 Clinicaltrials.gov. [cited 2021 Jan 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03459469?term=Tegavivint&draw=2&rank=1"},{"key":"cit0063","unstructured":"[cited 2021 Jan 2]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800048848"},{"key":"cit0064","unstructured":"Phase I clinical study of CWP232291 in acute myeloid leukemia patients. [cited 2021 May 11]. Available from: https:\/\/wwwclinicaltrialsgov\/ct2\/show\/NCT01398462?term=CWP232291&draw=2&rank=3"},{"key":"cit0065","unstructured":"Phase I study of radiolabeled OTSA101-DTPA in patients with relapsed or refractory Synovial Sarcoma; [cited 2021 May 11]. Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04176016?term=OTSA101-DTPA-90Y&draw=2&rank=1"},{"key":"cit0066","unstructured":"A dose escalation study of OMP-18R5 in subjects with solid tumors. Available from clinicaltrials.gov.in. [cited 2021 May 11]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01345201?term=OMP-18R5&draw=2&rank=1"},{"key":"cit0067","unstructured":"A dose escalation study of OMP-54F28 in subjects with solid tumors. Available from clinicaltrials.gov.in. [cited 2021 May 11]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01608867?term=OMP-54F28&draw=2&rank=4"},{"key":"cit0068","unstructured":"Samumed. 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof WO2014110086, 2014."},{"key":"cit0069","unstructured":"Samumed. gamma-diketones as wnt\/beta -catenin signaling pathway activators.WO2014130869, 2014."},{"key":"cit0070","unstructured":"Samumed. 5-Substituted indazole-3-carboxamides and preparation and use thereof WO2015143380, 2015."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0074","unstructured":"Samumed. 3-(3H-Imidazo[4,5-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridine and therapeutic uses thereof WO2016040184, 2016."},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0079","unstructured":"Samumed. 3-(1H-Imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017023972, 2017."},{"key":"cit0080","unstructured":"Samumed. 3-(1H-Indol-2-yl)-1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof WO 2017023973, 2017."},{"key":"cit0081","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-c]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridines and therapeutic uses thereof WO 2017023975, 2017."},{"key":"cit0082","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridines and therapeutic uses thereof WO 2017023980, 2017."},{"key":"cit0083","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof WO 2017023981, 2017."},{"key":"cit0084","unstructured":"Samumed. 3-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-1H-pyrazolo[3,4-c]pyridines and therapeutic uses thereof WO 2017023984, 2017."},{"key":"cit0085","unstructured":"Samumed. 3-(1H-Indol-2-yl)-1H-indazoles and therapeutic uses thereof WO 2017023986, 2017."},{"key":"cit0086","unstructured":"Samumed. 3-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof WO 2017023987, 2017."},{"key":"cit0087","unstructured":"Samumed. 3-(3H-Imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017023988, 2017."},{"key":"cit0088","unstructured":"Samumed. 3-(1H-Benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017023989, 2017."},{"key":"cit0089","unstructured":"Samumed. 3-(1H-Indol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017023993, 2017."},{"key":"cit0090","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof WO 2017023996, 2017."},{"key":"cit0091","unstructured":"Samumed. 3-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017024003, 2017."},{"key":"cit0092","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof.WO 2017024004, 2017."},{"key":"cit0093","unstructured":"Samumed. 3-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-1H-indazoles and therapeutic uses thereof WO 2017024010, 2017."},{"key":"cit0094","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-c]pyridin-2-yl)-1H-indazoles and therapeutic uses thereof WO 2017024013, 2017."},{"key":"cit0095","unstructured":"Samumed. 3-(3H-Imidazo[4,5-b]pyridin-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017024015, 2017."},{"key":"cit0096","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-b]pyridin-2-yl)-1H-indazoles and therapeutic uses thereof WO 2017024021, 2017."},{"key":"cit0097","unstructured":"Samumed. 3-(1H-Pyrrolo[2,3-c]pyridin-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof WO 2017024025, 2017."},{"key":"cit0098","unstructured":"Samumed. 3-(1H-Indol-2-yl)-1H-pyrazolo[3,4-c]pyridines and therapeutic uses thereof WO 2017024026, 2017."},{"key":"cit0099","unstructured":"Samumed. Isoquinolin-3-yl carboxamides and preparation and use thereof WO 2017189829, 2017."},{"key":"cit0100","unstructured":"Samumed. 6-(5-Membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof WO 2019079626, 2019."},{"key":"cit0101","unstructured":"Samumed. 6-(5-Membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof WO 2019084496, 2019."},{"key":"cit0102","unstructured":"Samumed. 6-(6-Membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof WO 2019084497, 2019."},{"key":"cit0103","unstructured":"Samumed. Diazanaphthalen-3-yl carboxamides and preparation and use thereof.WO 2019089835, 2019."},{"key":"cit0104","unstructured":"Samumed. Indazole containing macrocycles and therapeutic uses thereof WO 2019241540, 2019."},{"key":"cit0105","unstructured":"Samumed. Pyrazole derivatives as modulators of the Wnt\/b-catenin signaling pathway WO 2020150545, 2020."},{"key":"cit0106","unstructured":"Bayer. Novel compounds WO 2014147182, 2014."},{"key":"cit0107","unstructured":"Bayer. Novel compounds WO 2014147021, 2014."},{"key":"cit0108","unstructured":"Bayer. Novel compounds WO 2015140195, 2015."},{"key":"cit0109","unstructured":"Bayer. Inhibitors of the Wnt signalling pathways WO 2015140196, 2015."},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0113","unstructured":"Bayer. Substituted 3-phenylquinazolin-4(3H)-ones and uses thereof WO 2019063704, 2019."},{"key":"cit0114","unstructured":"Bayer. Substituted 3-phenylquinazolin-4(3H)-ones and uses thereof WO 2019063708, 2019."},{"key":"cit0115","unstructured":"A*STAR. Wnt pathway modulators WO 2014175832, 2014."},{"key":"cit0116","unstructured":"A*STAR. Purine diones as Wnt pathway modulators.WO 2014189466, 2014."},{"key":"cit0117","unstructured":"A*STAR. maleimide derivatives as modulators of wnt pathway.WO 2015094118, 2015."},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.D002790"},{"key":"cit0119","unstructured":"A*STAR. wnt pathway modulators. WO 2015094119, 2015."},{"key":"cit0120","unstructured":"A*STAR. phthalimide derivatives as modulators of wnt pathway. WO 2015187094, 2015."},{"key":"cit0121","unstructured":"A*STAR. wnt pathway modulators. WO 2019054941, 2019."},{"key":"cit0122","unstructured":"Institute HLMCCaR. Inhibitors for the beta-catenin\/B-cell lymphoma 9 (BCL9) protein-protein interaction WO 2019118961, 2019."},{"key":"cit0123","unstructured":"Institute HLMCCaR. inhibitors for the \u03b2-catenin\/b-cell lymphoma 9 (bcl9) protein\u2013protein interaction.WO2019139961, 2019."},{"key":"cit0124","unstructured":"Institute HLMCCaR. \u03b2eta-catenin and b-cell lymphoma 9 (bcl9) inhibitors.WO2020081917, 2020."},{"key":"cit0125","unstructured":"Institute HLMCCaR. \u03b2eta-catenin and b-cell lymphoma 9 (bcl9) inhibitors.WO2020081918, 2020."},{"key":"cit0126","unstructured":"Institute HLMCCaR. inhibitors for the \u03b2-catenin\/t-cell factor protein\u2013protein interaction inhibitors.WO2019191410, 2019."},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-0773-7_9"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01324"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00068"},{"key":"cit0130","unstructured":"Institute HLMCCaR. peptidomimetic inhibitors of \u03b2-catenin\/tcf protein\u2013protein interaction.WO2020118179, 2020."},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00147"},{"key":"cit0132","unstructured":"Merck. 2-aminopyridine compounds.WO 2014063778, 2014."},{"key":"cit0133","unstructured":"Merck. azaheterobicyclic compounds.WO2014086453, 2014."},{"key":"cit0134","unstructured":"Merck. pyridyl piperidines.WO2015144290, 2015."},{"key":"cit0135","unstructured":"Duke U. new methods of use for an anti-diarrhea agent.WO 2016210247, 2016."},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3978"},{"key":"cit0138","unstructured":"Duke U. niclosamide analogues and therapeutic use thereof.WO2020028392, 2020."},{"key":"cit0139","unstructured":"Curegenix. compounds for treatment of cancer.WO2014165232, 2014."},{"key":"cit0140","unstructured":"Curegenix. compounds for treatment of fibrosis diseases.WO2014159733, 2014."},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0142","unstructured":"Newyork U. novel oxazole and thiazole compounds as \u03b2-catenin modulators and uses thereof.WO2017152032, 2017."},{"key":"cit0143","doi-asserted-by":"publisher","DOI":"10.1021\/jm400159c"},{"key":"cit0144","unstructured":"University T. Highly potent inhibitors of porcupine WO 2014186450, 2014."},{"key":"cit0145","unstructured":"University T. disubstituted and trisubtituted 1,2,3-triazoles as wnt inhibitors.WO2018045182, 2018."},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"cit0148","unstructured":"Hangzhou. Wnt pathway inhibitor embedded with ureas structure WO2017097215, 2017."},{"key":"cit0149","unstructured":"Hangzhou. Five-membered heterocyclic amides Wnt pathway inhibitor WO 2017097216, 2017."},{"key":"cit0150","unstructured":"Suzhou. Wnt signaling pathway inhibitors and therapeutic applications thereof WO 2017062688, 2017."},{"key":"cit0151","unstructured":"Suzhou. 3-fluoropyridine heterocyclic compound and application thereof. WO 2017167150, 2017."},{"key":"cit0152","unstructured":"Shanghai IfBS. 15-Oxospiramilactone derivatives, preparation method therefor, and uses thereof WO 2014169711, 2014."},{"key":"cit0153","unstructured":"Carna B Novel quinazoline derivative WO2015083833, 2015."},{"key":"cit0154","unstructured":"Prism B (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound WO2015098853, 2015."},{"key":"cit0155","unstructured":"Sichuan. Substituted dihydrobenzofuran-piperidine-ketone derivative, preparation and use thereof WO2015135461, 2015."},{"key":"cit0156","unstructured":"Kyowa. Wnt signaling inhibitor. WO 2015016195, 2015."},{"key":"cit0157","unstructured":"University M. wnt signaling pathway inhibitors for treatments of disease. WO 20170151786, 2017."},{"key":"cit0158","unstructured":"University T. Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis WO2017047762, 2017."},{"key":"cit0159","unstructured":"southern RI. Benzimidazole compounds, use as inhibitors of Wnt signaling pathway in cancers, and methods for preparation thereof WO 2017132511, 2017."},{"key":"cit0160","unstructured":"University c. Inhibitors of the wnt\/beta-catenin pathway.WO2019152536, 2019."},{"key":"cit0161","unstructured":"University L. Pyrazole derivatives as inhibitors of the Wnt signalling pathway. WO 2019166616, 2019."},{"key":"cit0162","unstructured":"Huihan. Compound as WNT signal pathway inhibitor and medical use thereof WO 2020125759, 2020."},{"key":"cit0163","unstructured":"Kyoto. Wnt signaling pathway inhibitor WO2020130119, 2020."},{"key":"cit0164","unstructured":"Nantbio. A dual inhibitor of Wnt\/beta-catenin and sonic hedgehog signal transduction pathways WO2020072540, 2020."},{"key":"cit0165","unstructured":"Surrozen. Wnt surrogate molecules and uses threof.WO 2019126398A1, 2019."},{"key":"cit0166","unstructured":"Surrozen. Anti LRP-5\/6 antibodies and methods of use.WO 2019126401, 2019."},{"key":"cit0167","unstructured":"Surrozen. Modulation of Wnt signaling in ocular disorders.WO 2020167848A1, 2020."},{"key":"cit0168","unstructured":"Surrozen. Modulation of Wnt signaling in gastrointestinal disorders. WO 2020185960, 2020."},{"key":"cit0169","unstructured":"Texas U. Monoclonal antibodies against human dickkopf3 and uses thereof.WO 2020081579 2020."},{"key":"cit0170","unstructured":"Texas U. Monoclonal antibodies against MHC-bound human dickkopf-1 peptides and uses thereof. WO 2020160532, 2020."},{"key":"cit0171","unstructured":"Yale U. Humanized anti-dkk2 antibody and uses thereof WO 2017074774, 2017."},{"key":"cit0172","unstructured":"Yale U. Low density lipoprotein receptor related protein 5 inhibition suppresses tumor formation. WO2018174984, 2018."},{"key":"cit0173","unstructured":"BIOMEDICINE R. Binding molecules that inhibit cancer growth.WO 2017069628, 2017."},{"key":"cit0174","unstructured":"Boehringer G. Biparatopic polypeptides antagonizing Wnt signaling in tumor cells.WO 2017093478, 2017."},{"key":"cit0175","unstructured":"therapeutics A. Biparatopic polypeptides antagonizing Wnt signaling in tumor cells.WO2017093478, 2017."},{"key":"cit0176","unstructured":"California Uo. Methods and compositions for treating alzheimer\u2019s disease.WO 2020263862, 2020."},{"key":"cit0177","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.03.088"},{"key":"cit0178","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjt049"},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mju002"},{"key":"cit0180","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-018-0017-8"},{"key":"cit0181","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00170"},{"key":"cit0182","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.01.028"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2021.1940138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:32:20Z","timestamp":1635316340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2021.1940138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":182,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,2]]}},"alternative-id":["10.1080\/13543776.2021.1940138"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2021.1940138","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}